This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity, diabetes, and a common type of heart failure, boosting Novo’s attempt to get the popular drug approved for yet another usage beyond weight loss. The study, being presented here on Saturday at the American College of Cardiology conference and published in the New England Journal of Medicine , reports results from the second large trial Novo has conducted on Wegovy in heart fai
Under this new partnership, Dr Reddy’s will market the drug under a second brand name Gantra in India, expanding the reach of vericiguat to meet the needs of patients with Chronic Heart Failure with reduced ejection fraction (less than 45 per cent) Dr Reddy’s Laboratories and Bayer announced that both companies have entered into a partnership to market and distribute a second brand of Vericiguat in India.
STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “For national security, the U.S.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation, pain, and joint destruction, significantly impacting patients’ quality of
Annual Drug Patent Expirations for ORACEA Oracea is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers.
52
52
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Annual Drug Patent Expirations for ORACEA Oracea is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers.
CASE STUDY Effective Customer Communication - Launching a New Drug in Rural India Table of Contents Case Study Introduction: As the leader of the marketing team at ABCG Pharmaceuticals, you oversee the launch of a groundbreaking new drug designed to address a prevalent health issue in rural India. Effective communication with healthcare providers and patients in remote areas is essential to ensure the successful adoption and utilization of the new medication.
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation, pain, and joint destruction, significantly impacting patients’ quality of life. While existing medications offer relief, they often come with side effects. Low-Dose Naltrexone (LDN) emerges as a potential alternative for RA patients seeking safer and more effective treatment options.
Although the number of clinical trials has quadrupled, the number of FDA approvals remains stable over a 10-year period, highlighting workforce challenges in clinical research.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
358 
Let's personalize your content